Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Arm, Multicenter, Phase III Study on the Efficacy, Safety, and Pharmacokinetics of FP-001 42 mg Controlled Release in Patients With Central (Gonadotropin-Dependent) Precocious Puberty (Casppian Study)

NCT05493709 is registered in ClinicalTrials.gov with Foresee Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05493709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05493709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Arm, Multicenter, Phase III Study on the Efficacy, Safety, and Pharmacokinetics of FP-001 42 mg Controlled Release in Patients With Central (Gonadotropin-Dependent) Precocious Puberty (Casppian Study)
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
June 2, 2023
Completion date
May 24, 2026
Enrollment
94 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

puberty; precocious, central